Skip to main content
. 2013 Apr 20;18(12):1444–1462. doi: 10.1089/ars.2012.4907

Table 1.

Compounds Acting at N-Methyl-d-Aspartate Glutamate Receptors As Agonists and Antagonists

Selective agonists (glutamate site) NMDA, aspartate, D,L(tetrazol-5-yl)glycine, homoquinolinic acid (partial agonist)
Selective antagonists (glutamate site) D-AP5, CGS19755, CGP37849, LY233053, d-CCPene (NR2A=NR2B>NR2C=NR2D); PPDA (NR2C=NR2D>NR2B=NR2A); NVP-AAM077 (NR2A>NR2C>NR2D>NR2B); conantokin-G (NR2B>NR2D=NR2C=NR2A)
Selective agonists (glycine site) Glycine, D-serine, (+)-HA966 (partial agonist)
Selective antagonists (glycine site) 5,7-Dichlorokynurenate, L689560, L701324, GV196771A
Channel blockers Mg2+, MK-801, ketamine, phencyclidine, memantine, amantidine, N1-dansylspermine (NR2A=NR2B>> NR2C=NR2D)

Listed are some of the available compounds that have been used to modify NMDAR activity in vitro and in vivo [modified from (252)]. Relative affinities are specified in parenthesis.

NMDAR, N-methyl-d-aspartate glutamate receptor.